Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2006
Business Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates in two main segments: Hematology (controls and calibrators for blood analysis instruments) and Biotechnology (cytokines, antibodies, and assay kits for research and diagnostics). In July 2005, the company acquired Fortron Bio Science, Inc. and BiosPacific, Inc., expanding its biotechnology portfolio and diagnostic market presence.
Key Financial Metrics
| Metric (in thousands, except per share) | Fiscal 2006 | Fiscal 2005 |
|---|---|---|
| Net Sales | $202,617 | $178,652 |
| Gross Margin | $156,899 (77.4%) | $141,839 (79.4%) |
| Operating Income | $108,503 | $97,763 |
| Net Earnings | $73,351 | $66,132 |
| Diluted EPS | $1.85 | $1.62 |
| Cash from Operations | $85,589 | $74,443 |
| Total Assets | $370,512 | $295,263 |
| Long-Term Debt | $12,198 | $13,378 |
| Cash & Investments | $108,846 | $97,134 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.4% to $202.6 million, driven primarily by a 20.9% increase in Biotechnology sales ($134.4 million). The acquisitions of Fortron and BiosPacific contributed approximately $9.4 million to sales.
- Profitability: Net earnings rose 10.9% to $73.4 million. However, the consolidated gross margin percentage declined from 79.4% to 77.4%. This decrease was largely due to purchase accounting adjustments related to the Fortron and BiosPacific acquisitions, which resulted in a $1.7 million write-up of acquired inventory.
- Segment Performance:
- Biotechnology: Sales grew significantly due to volume increases and acquisitions.
- R&D Europe: Sales increased 3.2% in USD terms, though underlying sales in British pounds grew 7.8%. Currency fluctuations negatively impacted reported earnings by approximately $659,000.
- Hematology: Sales declined to $15.2 million (from $16.2 million) due to reduced sales to a specific OEM customer.
- Investments: The company increased its investment in ChemoCentryx, Inc. (CCX) to a total of $14.2 million (including a convertible note) and increased its stake in Hemerus Medical, LLC to 15%.
Guidance, Outlook, and Risks
- Outlook: Management expects to meet future cash requirements through existing funds and operating cash flow. Capital expenditures for fiscal 2007 are estimated at $4.7 million for equipment and $8.0 million for facility expansion in Minneapolis.
- Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) in fiscal 2006, resulting in $1.6 million of stock-based compensation expense, reducing net earnings by approximately $1.1 million compared to prior accounting methods.
- Risks and Contingencies:
- Legal Proceedings: Streck Laboratories, Inc. filed a patent infringement lawsuit in June 2006 regarding hematology controls. The company disputes the validity of the patents and is seeking an interference declaration.
- Market Risk: Approximately 25% of sales are in foreign currencies (primarily British Pound and Euro). A 10% fluctuation in exchange rates could impact annual operating income by approximately $1.4 million.
- Investment Risk: Significant investments in development-stage companies (CCX, Hemerus) carry the risk of impairment if these companies fail to secure funding or regulatory approval.
Investor Verification Checklist
- Acquisition Integration: Verify the long-term margin recovery of Fortron and BiosPacific following the initial purchase accounting inventory write-up.
- Legal Exposure: Monitor the status of the patent infringement lawsuit filed by Streck Laboratories regarding reticulocyte controls.
- Investment Valuation: Assess the financial health and funding status of ChemoCentryx, Inc. and Hemerus Medical, LLC, given the company's significant equity exposure ($17.2 million combined).
- Currency Sensitivity: Evaluate the impact of a strengthening U.S. dollar on future earnings from the European subsidiary.
- Stock-Based Compensation: Review the impact of SFAS 123R adoption on future earnings and the remaining unrecognized compensation cost ($367,000).